logo
  

Walgreens Says Pfizer COVID-19 Vaccine Booster Shots Now Available In U.S.

Walgreens said Friday that eligible individuals can now receive Pfizer COVID-19 booster vaccinations in stores nationwide, following the U.S. Food and Drug Administration Emergency Use Authorization and new guidance from the Centers for Disease Control and Prevention. Individuals can receive their flu and COVID-19 booster shots during the same appointment.

Eligible individuals can receive their booster shot at least six months after they completed their Pfizer COVID-19 primary vaccine series.

Individuals ages 65 and older; Long-term care facility residents ages 18 and older; Individuals ages 18 and older with underlying medical conditions. Individuals ages 18-64 who are at an increased risk for COVID-19 exposure and transmission because of occupational or institutional setting, such as healthcare and essential workers, are eligible to receive a booster dose at this time.

In addition, moderately to severely immunocompromised individuals who are already eligible to receive an additional dose of a Pfizer or Moderna COVID-19 vaccine can also receive a booster dose at least six months following their additional dose.

Walgreens said it is offering a $5 Walgreens Cash reward, when customer spend $20, after each vaccine received in store to individuals who have a registered myWalgreens account.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
RELATED NEWS
Follow RTT